Company / Shareholders' Equity
Crinetics Pharmaceuticals, Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$992.1M
FY2025
5-year range
$316.3M / $1.3B
FY2021-FY2025
Trend
-25.1%
vs FY2024
Sector context
#49 of 213
Health Care
What the data says
Crinetics Pharmaceuticals, Inc.'s shareholders' equity of $992M is higher than 77% of companies in the Health Care sector (FY2025). Shareholders' Equity has fluctuated over the past 10 years, ranging from -$15M in FY2019 to $1.3B in FY2024.
Based on SEC 10-K filings.
$992M in FY2025 with a 5-year CAGR of +44.0%. Top quartile in the Health Care sector.
Improved from $539M to $992M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +46.4%
- 5-Year CAGR
- +44.0%
- 10-Year CAGR
- -
Sector benchmark
-61.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +44.0%, indicating consistent growth.
- In FY2025, shareholders' equity decreased 25.1% year-over-year.
- Ranks #49 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $992.1M | -25.1% |
| FY2024 | $1.3B | +145.7% |
| FY2023 | $539.1M | +70.4% |
| FY2022 | $316.3M | -4.7% |
| FY2021 | $331.9M | +107.2% |
| FY2020 | $160.2M | +1166.6% |
| FY2019 | -$15.0M | -142.1% |
| FY2018 | -$6.2M | +58.7% |
| FY2017 | -$15.0M | -142.1% |
| FY2016 | -$6.2M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026